US-based CiceroDx has introduced a new test panel called ReceptivaDx to diagnose causes of unexplained infertility in women.

With the new test, the firm intends to provide a cost-effective solution for in-vitro fertilisation (IVF) centres and healthcare providers to detect barriers to implantation such as endometriosis.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Reportedly, 15-30% of women undergoing evaluation for infertility have an unidentified cause, and endometriosis is said to be associated with around 50% of all unexplained infertility cases.

The new ReceptivaDx assay uses an endometrial biopsy sample and delivers results in three to five days, unlike existing diagnostic techniques that require the use of an expensive and invasive surgical procedure called laparoscopy to identify endometriosis.

The early identification of the condition is expected to assist IVF centres in determining appropriate treatment options, leading to an increase in success rates.

See Also:

"The new ReceptivaDx assay uses an endometrial biopsy sample and delivers results in three to five days."

CiceroDx CEO Chris Jackson said: “Our mission at CiceroDx is to ensure we deliver the most accurate and cost-effective diagnostic tools for doctors and families looking for answers to unexplained infertility and implantation failure.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Helping resolve infertility issues is just the first step. Our goal is to help clinicians better detect endometriosis in the millions of women who suffer from this silent epidemic every day.”

The firm holds the exclusive licence to distribute and market the ReceptivaDx test.

CiceroDx scientific advisor Bruce Lessey further added: “ReceptivaDx is a breakthrough test and provides a unique, enhanced screening opportunity."

The test is currently available at more than 75 IVF centres in the US, Canada, Europe and South America.